Novocure GmbH
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$13.5M
Doctors Paid
299
Transactions
2,128
2024 Total
$4.8M
Payment Breakdown by Category
Research$13.1M (97.1%)
Consulting$280,924 (2.1%)
Travel$3,112 (0.0%)
Food & Beverage$2,312 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13.1M | 1,776 | 97.1% |
| Consulting Fee | $280,924 | 58 | 2.1% |
| Honoraria | $111,907 | 261 | 0.8% |
| Travel and Lodging | $3,112 | 8 | 0.0% |
| Food and Beverage | $2,312 | 25 | 0.0% |
Payments by Type
Research
$13.1M
1,776 transactions
General
$398,256
352 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma | $9.9M | 0 | 1,570 |
| EF-25 Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC) | $350,702 | 0 | 57 |
| EF-36 A Pilot, Randomized,Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab for First LineTreatment of Advanced or Metastatic Non-Small Cell Lung Cancer | $306,456 | 0 | 41 |
| EF-36 A pilot, single arm, open-label study of Tumor Treating Fields (TTFields,150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer | $268,032 | 0 | 17 |
| EF-36 a pilot, randomized, open-label study evaluating the safety and effectiveness of Tumor Treating Fields (TTFields) with pembrolizumab for first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC). | $211,421 | 0 | 44 |
| MAXPOINTTM software beta version testing protocol | $155,000 | 0 | 12 |
| Determining the efficacy of using the Inovivo system to enhance the efficacy of checkpoint inhibitor treatment in glioblastoma mouse models | $118,500 | 0 | 1 |
| EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150lHz) concomitant with gemcitabine and nab-paclitaxel) for front-line treatment of locally-advanced pancreatic adenocarcinoma | $25,435 | 0 | 3 |
| EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma | $18,394 | 0 | 2 |
| A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant withpembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer | $13,500 | 0 | 1 |
| EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. | $1,897 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Radiation Oncology | $157,002 | 7 | $22,429 |
| Medical Oncology | $55,490 | 50 | $1,110 |
| Neurological Surgery | $52,500 | 1 | $52,500 |
| Gynecologic Oncology | $40,660 | 9 | $4,518 |
| Hematology & Oncology | $37,170 | 134 | $277.38 |
| Obstetrics & Gynecology | $17,801 | 5 | $3,560 |
| Thoracic Surgery (Cardiothoracic Vascular Surgery) | $9,452 | 1 | $9,452 |
| Internal Medicine | $8,261 | 40 | $206.53 |
| Neurology | $7,238 | 5 | $1,448 |
| Dermatology | $2,400 | 1 | $2,400 |
| Specialist | $1,850 | 9 | $205.56 |
| Hematology | $1,600 | 8 | $200.00 |
| Family | $1,100 | 5 | $220.00 |
| Student in an Organized Health Care Education/Training Program | $1,050 | 5 | $210.00 |
| Emergency Medicine | $634.30 | 2 | $317.15 |
| Nurse Practitioner | $500.00 | 2 | $250.00 |
| Hospice and Palliative Medicine | $450.00 | 2 | $225.00 |
| Surgery | $400.00 | 1 | $400.00 |
| Hospitalist | $338.89 | 2 | $169.45 |
| Critical Care Medicine | $316.67 | 1 | $316.67 |
| Pulmonary Disease | $291.67 | 1 | $291.67 |
| Adult Health | $250.00 | 1 | $250.00 |
| Physician Assistant | $250.00 | 1 | $250.00 |
| Registered Nurse | $250.00 | 1 | $250.00 |
| Geriatric Medicine | $200.00 | 1 | $200.00 |
| Medical | $200.00 | 1 | $200.00 |
| Oncology | $200.00 | 1 | $200.00 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Dr. Amir Lavaf, M.d, M.D | Radiation Oncology | Palm Springs, CA | $80,250 | $0 |
| Steven Toms, Md, MD | Neurological Surgery | North Dartmouth, MA | $52,500 | $0 |
| Wenyin Shi, Md, Phd, MD, PHD | Radiation Oncology | Philadelphia, PA | $27,500 | $0 |
| Anne Tsao, M.d, M.D | Medical Oncology | Houston, TX | $22,800 | $0 |
| Paul Derose, M.d, M.D | Radiation Oncology | Richardson, TX | $22,500 | $0 |
| Dr. Alexander Whitley, Md Phd, MD PHD | Radiation Oncology | Montgomery, AL | $15,750 | $0 |
| Robert Coleman, M.d, M.D | Gynecologic Oncology | Houston, TX | $11,565 | $0 |
| Dr. Prasad Adusumilli, M.d, M.D | Thoracic Surgery (Cardiothoracic Vascular Surgery) | New York, NY | $9,452 | $0 |
| Dr. David Tran, Md Phd, MD PHD | Medical Oncology | Los Angeles, CA | $9,341 | $0 |
| Dr. Brian Slomovitz, M.d, M.D | Gynecologic Oncology | Fort Lauderdale, FL | $7,965 | $0 |
| David O'malley, M.d, M.D | Gynecologic Oncology | Hilliard, OH | $7,692 | $0 |
| Jonathan Berek, Md, MD | Obstetrics & Gynecology | Stanford, CA | $6,720 | $0 |
| Kathleen Moore, Md, MD | Obstetrics & Gynecology | Oklahoma City, OK | $6,072 | $0 |
| Rupesh Kotecha, M.d, M.D | Radiation Oncology | Miami, FL | $5,602 | $0 |
| Joel Neal, M.d., Ph.d, M.D., PH.D | Hematology & Oncology | Stanford, CA | $4,770 | $0 |
| Dr. Joshua Sabari, M.d, M.D | Hematology & Oncology | New York, NY | $3,776 | $0 |
| Dr. Jeffrey Ward, Md, MD | Medical Oncology | Saint Louis, MO | $3,500 | $0 |
| Sami Diab, Md, MD | Medical Oncology | Aurora, CO | $3,500 | $0 |
| Bradley Monk, Md, MD | Gynecologic Oncology | West Palm Beach, FL | $3,330 | $0 |
| Dr. Seema Nagpal, M.d, M.D | Neurology | Stanford, CA | $3,250 | $0 |
| Lawrence Kleinberg, M.d, M.D | Radiation Oncology | Baltimore, MD | $3,000 | $0 |
| Bhavana Pothuri, M.d, M.D | Gynecologic Oncology | New York, NY | $2,802 | $0 |
| Samuel Goldlust, Md, MD | Neurology | Kansas City, MO | $2,750 | $0 |
| Dr. Premal Thaker, Md, MD | Gynecologic Oncology | Saint Louis, MO | $2,436 | $0 |
| Dr. Ramez Eskander, M.d, M.D | Obstetrics & Gynecology | Encinitas, CA | $2,400 | $0 |
Ad
Top Products
- Optune $1.1M
- Optune Lua (NovoTTF-200T) $643.58
Payment Categories
- Food & Beverage $2,312
- Consulting $280,924
- Travel & Lodging $3,112
- Research $13.1M
About Novocure GmbH
Novocure GmbH has made $13.5M in payments to 299 healthcare providers, recorded across 2,128 transactions in the CMS Open Payments database. In 2024, the company paid $4.8M. The top product by payment volume is Optune ($1.1M).
Payments were distributed across 27 medical specialties. The top specialty by payment amount is Radiation Oncology ($157,002 to 7 doctors).
Payment categories include: Food & Beverage ($2,312), Consulting ($280,924), Research ($13.1M), Travel & Lodging ($3,112).